Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s40265-019-01114-z.

Title:
Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | Drugs
Description:
Our aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies. A systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on lipoproteins, and the safety profile of mipomersen. Effect sizes for lipid changes were expressed as weighted mean differences (WMD) and 95% confidence intervals (CI). For safety analysis, odd ratios (OR) and 95% CI were calculated using the Mantel–Haenszel method. Data were pooled from 13 clinical studies comprising 49 arms, which included 1053 subjects overall, with 729 in the active-treated arm and 324 in the control arm. Meta-analysis of data suggested that mipomersen significantly reduced low-density lipoprotein cholesterol (WMD βˆ’ 1.52, 95% CI βˆ’ 1.85 to βˆ’ 1.19; p < 0.001), total cholesterol (WMD βˆ’ 1.55, 95% CI βˆ’ 1.97 to βˆ’ 1.13; p < 0.001), non-high-density lipoprotein cholesterol (non-HDL-C) (WMD βˆ’ 1.66, 95% CI βˆ’ 2.06 to βˆ’ 1.27; p < 0.001), lipoprotein(a) (WMD βˆ’ 0.99, 95% CI βˆ’ 1.37 to βˆ’ 0.62; p < 0.001), apolipoprotein B (WMD βˆ’ 1.66, 95% CI βˆ’ 2.04 to βˆ’ 1.27; p < 0.001), triglycerides (WMD –0.61, 95% CI βˆ’ 0.76 to βˆ’ 0.46, p < 0.001), very-low-density lipoprotein cholesterol (WMD βˆ’ 0.58, 95% CI βˆ’ 0.73 to βˆ’ 0.43; p < 0.001) and apolipoprotein A-I (WMD βˆ’ 0.25, 95% CI βˆ’ 0.51 to βˆ’ 0.001; p = 0.049) without affecting HDL-C levels (WMD 0.11, 95% CI βˆ’ 0.03 to 0.26; p = 0.124). However, treatment with mipomersen was positively associated with an increased risk of discontinuation of treatment (OR 3.02, 95% CI 1.96–4.65; p < 0.001), injection-site reaction (OR 11.41, 95% CI 7.88–16.52; p < 0.001), hepatic steatosis (OR 4.96, 95% CI 1.99–12.39; p = 0.001), hepatic enzymes elevation (OR 3.61, 95% CI 2.09–6.24; p < 0.001) and flu-like symptoms (OR 2.02, 95% CI 1.45–2.81; p < 0.001). Despite favourable effects on the lipid profile, some concerns are reinforced from the safety profile. As a matter of fact, mipomersen therapy is more likely discontinued and associated with increased risk of injection-site reactions, hepatic steatosis, hepatic enzyme elevation, and flu-like symptoms.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Education
  • Health & Fitness
  • Insurance

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

The income method remains a mystery to us.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {πŸ”}

article, pubmed, google, scholar, cas, mipomersen, familial, patients, hypercholesterolemia, safety, metaanalysis, apolipoprotein, hypercholesterolaemia, efficacy, atherosclerosis, homozygous, central, randomized, clinical, trials, lipoprotein, heart, kastelein, systematic, wmd, cholesterol, raal, santos, inhibition, effect, lipid, treatment, therapy, disease, lancet, inhibitor, fogacci, hovingh, stroes, eur, blom, placebocontrolled, synthesis, european, review, watts, catapano, clin, cardiol, stein,

Topics {βœ’οΈ}

simple funnel-plot–based method month download article/chapter high-risk statin-intolerant patients google scholar databases low-density lipoprotein cholesterol low-density lipoprotein cholesterol high-density lipoprotein cholesterol esc/eas task force open-label taussig study high-dose statin therapy article drugs aims randomized placebo-controlled study full article pdf low-density lipoprotein massimiliano ruscica mantel–haenszel method privacy choices/manage cookies article fogacci federica fogacci randomized controlled trials long-term mipomersen treatment european atherosclerosis society open-label extension randomized clinical trials liver triglyceride content 2016 esc/eas guidelines cholesterol-lowering medication european economic area european prospective investigation placebo-controlled trial conventional drug therapy surgical sciences department biomolecular sciences department raal fj high cardiovascular risk expert opin pharmacother cholesterol-lowering treatment ldl cholesterol concentrations related subjects short-term administration kondapally seshasai sr aguilar-salinas ca curr atheroscler rep preferred reporting items diabetes obes metab plasma homocysteine levels author correspondence cholesterol treatment trialists pubmed medline systematic literature search

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
         description:Our aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies. A systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on lipoproteins, and the safety profile of mipomersen. Effect sizes for lipid changes were expressed as weighted mean differences (WMD) and 95% confidence intervals (CI). For safety analysis, odd ratios (OR) and 95% CI were calculated using the Mantel–Haenszel method. Data were pooled from 13 clinical studies comprising 49 arms, which included 1053 subjects overall, with 729 in the active-treated arm and 324 in the control arm. Meta-analysis of data suggested that mipomersen significantly reduced low-density lipoprotein cholesterol (WMD βˆ’Β 1.52, 95% CI βˆ’Β 1.85 to βˆ’Β 1.19; p < 0.001), total cholesterol (WMD βˆ’Β 1.55, 95% CI βˆ’Β 1.97 to βˆ’Β 1.13; p < 0.001), non-high-density lipoprotein cholesterol (non-HDL-C) (WMD βˆ’Β 1.66, 95% CI βˆ’Β 2.06 to βˆ’Β 1.27; p < 0.001), lipoprotein(a) (WMD βˆ’Β 0.99, 95% CI βˆ’Β 1.37 to βˆ’Β 0.62; p < 0.001), apolipoprotein B (WMD βˆ’Β 1.66, 95% CI βˆ’Β 2.04 to βˆ’Β 1.27; p < 0.001), triglycerides (WMD –0.61, 95% CI βˆ’Β 0.76 to βˆ’Β 0.46, p < 0.001), very-low-density lipoprotein cholesterol (WMD βˆ’Β 0.58, 95% CI βˆ’Β 0.73 to βˆ’Β 0.43; p < 0.001) and apolipoprotein A-I (WMD βˆ’Β 0.25, 95% CI βˆ’Β 0.51 to βˆ’Β 0.001; p = 0.049) without affecting HDL-C levels (WMD 0.11, 95% CI βˆ’Β 0.03 to 0.26; p = 0.124). However, treatment with mipomersen was positively associated with an increased risk of discontinuation of treatment (OR 3.02, 95% CI 1.96–4.65; p < 0.001), injection-site reaction (OR 11.41, 95% CI 7.88–16.52; p < 0.001), hepatic steatosis (OR 4.96, 95% CI 1.99–12.39; p = 0.001), hepatic enzymes elevation (OR 3.61, 95% CI 2.09–6.24; p < 0.001) and flu-like symptoms (OR 2.02, 95% CI 1.45–2.81; p < 0.001). Despite favourable effects on the lipid profile, some concerns are reinforced from the safety profile. As a matter of fact, mipomersen therapy is more likely discontinued and associated with increased risk of injection-site reactions, hepatic steatosis, hepatic enzyme elevation, and flu-like symptoms.
         datePublished:2019-04-15T00:00:00Z
         dateModified:2019-04-15T00:00:00Z
         pageStart:751
         pageEnd:766
         sameAs:https://doi.org/10.1007/s40265-019-01114-z
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig6_HTML.png
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:79
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Federica Fogacci
               affiliation:
                     name:University of Bologna
                     address:
                        name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nicola Ferri
               affiliation:
                     name:University of Padua
                     address:
                        name:Drug Sciences Department, University of Padua, Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter P. Toth
               affiliation:
                     name:CGH Medical Center
                     address:
                        name:CGH Medical Center, Sterling, USA
                        type:PostalAddress
                     type:Organization
                     name:Johns Hopkins University School of Medicine
                     address:
                        name:Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Massimiliano Ruscica
               affiliation:
                     name:University of Milan
                     address:
                        name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alberto Corsini
               affiliation:
                     name:University of Milan
                     address:
                        name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
                     name:IRCCS Multimedica
                     address:
                        name:IRCCS Multimedica, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arrigo F. G. Cicero
               affiliation:
                     name:University of Bologna
                     address:
                        name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
      description:Our aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies. A systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on lipoproteins, and the safety profile of mipomersen. Effect sizes for lipid changes were expressed as weighted mean differences (WMD) and 95% confidence intervals (CI). For safety analysis, odd ratios (OR) and 95% CI were calculated using the Mantel–Haenszel method. Data were pooled from 13 clinical studies comprising 49 arms, which included 1053 subjects overall, with 729 in the active-treated arm and 324 in the control arm. Meta-analysis of data suggested that mipomersen significantly reduced low-density lipoprotein cholesterol (WMD βˆ’Β 1.52, 95% CI βˆ’Β 1.85 to βˆ’Β 1.19; p < 0.001), total cholesterol (WMD βˆ’Β 1.55, 95% CI βˆ’Β 1.97 to βˆ’Β 1.13; p < 0.001), non-high-density lipoprotein cholesterol (non-HDL-C) (WMD βˆ’Β 1.66, 95% CI βˆ’Β 2.06 to βˆ’Β 1.27; p < 0.001), lipoprotein(a) (WMD βˆ’Β 0.99, 95% CI βˆ’Β 1.37 to βˆ’Β 0.62; p < 0.001), apolipoprotein B (WMD βˆ’Β 1.66, 95% CI βˆ’Β 2.04 to βˆ’Β 1.27; p < 0.001), triglycerides (WMD –0.61, 95% CI βˆ’Β 0.76 to βˆ’Β 0.46, p < 0.001), very-low-density lipoprotein cholesterol (WMD βˆ’Β 0.58, 95% CI βˆ’Β 0.73 to βˆ’Β 0.43; p < 0.001) and apolipoprotein A-I (WMD βˆ’Β 0.25, 95% CI βˆ’Β 0.51 to βˆ’Β 0.001; p = 0.049) without affecting HDL-C levels (WMD 0.11, 95% CI βˆ’Β 0.03 to 0.26; p = 0.124). However, treatment with mipomersen was positively associated with an increased risk of discontinuation of treatment (OR 3.02, 95% CI 1.96–4.65; p < 0.001), injection-site reaction (OR 11.41, 95% CI 7.88–16.52; p < 0.001), hepatic steatosis (OR 4.96, 95% CI 1.99–12.39; p = 0.001), hepatic enzymes elevation (OR 3.61, 95% CI 2.09–6.24; p < 0.001) and flu-like symptoms (OR 2.02, 95% CI 1.45–2.81; p < 0.001). Despite favourable effects on the lipid profile, some concerns are reinforced from the safety profile. As a matter of fact, mipomersen therapy is more likely discontinued and associated with increased risk of injection-site reactions, hepatic steatosis, hepatic enzyme elevation, and flu-like symptoms.
      datePublished:2019-04-15T00:00:00Z
      dateModified:2019-04-15T00:00:00Z
      pageStart:751
      pageEnd:766
      sameAs:https://doi.org/10.1007/s40265-019-01114-z
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-01114-z/MediaObjects/40265_2019_1114_Fig6_HTML.png
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:79
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Federica Fogacci
            affiliation:
                  name:University of Bologna
                  address:
                     name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nicola Ferri
            affiliation:
                  name:University of Padua
                  address:
                     name:Drug Sciences Department, University of Padua, Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter P. Toth
            affiliation:
                  name:CGH Medical Center
                  address:
                     name:CGH Medical Center, Sterling, USA
                     type:PostalAddress
                  type:Organization
                  name:Johns Hopkins University School of Medicine
                  address:
                     name:Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Massimiliano Ruscica
            affiliation:
                  name:University of Milan
                  address:
                     name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alberto Corsini
            affiliation:
                  name:University of Milan
                  address:
                     name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
                  name:IRCCS Multimedica
                  address:
                     name:IRCCS Multimedica, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arrigo F. G. Cicero
            affiliation:
                  name:University of Bologna
                  address:
                     name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:79
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Bologna
      address:
         name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
         type:PostalAddress
      name:University of Padua
      address:
         name:Drug Sciences Department, University of Padua, Padua, Italy
         type:PostalAddress
      name:CGH Medical Center
      address:
         name:CGH Medical Center, Sterling, USA
         type:PostalAddress
      name:Johns Hopkins University School of Medicine
      address:
         name:Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA
         type:PostalAddress
      name:University of Milan
      address:
         name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
         type:PostalAddress
      name:University of Milan
      address:
         name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
         type:PostalAddress
      name:IRCCS Multimedica
      address:
         name:IRCCS Multimedica, Milan, Italy
         type:PostalAddress
      name:University of Bologna
      address:
         name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Federica Fogacci
      affiliation:
            name:University of Bologna
            address:
               name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
               type:PostalAddress
            type:Organization
      name:Nicola Ferri
      affiliation:
            name:University of Padua
            address:
               name:Drug Sciences Department, University of Padua, Padua, Italy
               type:PostalAddress
            type:Organization
      name:Peter P. Toth
      affiliation:
            name:CGH Medical Center
            address:
               name:CGH Medical Center, Sterling, USA
               type:PostalAddress
            type:Organization
            name:Johns Hopkins University School of Medicine
            address:
               name:Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Massimiliano Ruscica
      affiliation:
            name:University of Milan
            address:
               name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Alberto Corsini
      affiliation:
            name:University of Milan
            address:
               name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
            name:IRCCS Multimedica
            address:
               name:IRCCS Multimedica, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Arrigo F. G. Cicero
      affiliation:
            name:University of Bologna
            address:
               name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
      name:Drug Sciences Department, University of Padua, Padua, Italy
      name:CGH Medical Center, Sterling, USA
      name:Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA
      name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
      name:Pharmacological and Biomolecular Sciences Department, University of Milan, Milan, Italy
      name:IRCCS Multimedica, Milan, Italy
      name:Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(255)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

4.05s.